-
Nature: Immune cells resist the "essential" elements of COVID-19
Time of Update: 2020-12-18
dan Barouch, director of the BIDMC Center for Virology and Vaccine Research, and colleagues published a new paper in the journal Nature that sheds light on the role of antibodies and immune cells in rhesus monkeys in protecting SARS-CoV-2, the virus that causes COVID-19.
-
Sci Immunol: Gasdermin E is involved in a new mechanism of cell necross
Time of Update: 2020-12-18
researchers have revealed the activation mechanism of coral GSDME and its ability to perform cell coke death, as well as the causes of coral necrosis caused by its involvement in pathogens.
-
BCMA-CD3 dual-specific antibodies! Pfizer PF-0686315 Once a week subsethic injection to treat multiple myeloma: 83% total remission rate!
Time of Update: 2020-12-18
effective biotherapy target on the surface of multiple myeloma cells (pictured from literature: PMID: 30545798) had a total remission rate (ORR) of 80% in 20 patients treated at an effective dose range of 215-1000 μg/kg once a week.
-
The study found that the new endocrine peptide stimulates the plant's PTI immune response and disease mold resistance
Time of Update: 2020-12-18
Recently, Journal of Integrative Plant Biology published online a research article by a team of single-satellite professors at the Agricultural College entitled "The novel peptide NbPPI1 identified from Nicotiana benthamiana triggers immune responses and enhances resistance againstst Phytophthora pathogens".
-
Clin Lab: Blood tests have identified COVID-19-end biomarkers
Time of Update: 2020-12-18
8, 2020 // -- Researchers at the Seville Institute for Biomedical Research (IBIS) presented a study conducted in the Clinical Biochemistry Service at The University Hospital of Virgin del Rocio, which identified six biomarkers indicating that patients may have been infected with SARS-CoV-2.
-
GPRC5DxCD3 Dual-Specific Antibodies! Johnson talquetamab treatment of relapse or recurring multiple myeloma: total remission rate of 69%!
Time of Update: 2020-12-18
"GPRC5D is a new target for the treatment of multiple myeloma, and as a dual-specific antibody, talquetamab is becoming a potential treatment option for overtreated patients by targeting CD3 in combination with T cells," said Dr. Yusri Elsayed, Global Head of Hematology Malignancy at jansen Research and Development.
-
Nature sub-journal interpretation! Scientists have developed a new detector that can efficiently detect human fatty liver and liver fibrosis!
Time of Update: 2020-12-18
To develop an easy way to examine the liver disease, researcher Cima and colleagues modified a detector they had previously used to measure the level of hydro-cooperation in a patient's skeletal muscles before and after dialysis, using NMR to track magnetic changes in hydrogen atoms in muscle tissue.
-
CD20xCD3 dual-specific antibodies! Roche mosunetuzumab/glofitamab treats a variety of lymphomas: a total remission rate of 50-80%!
Time of Update: 2020-12-18
So far, in clinical trials, Roche's two CD20xCD3 T cells, combined with dual-specific antibodies mosunetuzumab and glofitamab, have shown good results in several types of NHL, including recurring or refractic (R/R) folioma (FL) and diffuse large B-cell lymphoma (DLBCL).
-
AJPCP: Developed a new tool to predict the recurrence of breast cancer
Time of Update: 2020-12-18
picture Source: Dr. In howard R.
researcher Petty says the new tool reduces overdiagnosis of life-threatening DCIS, while also allowing scientists to disrupt metabolic platforms in pharmacology, blocking tumor invasion and enhancing chemotherapy and radiotherapy to block tumor recurrence.
-
J Nut: Can daily intake of live bacteria improve physical health?
Time of Update: 2020-12-18
they explained that so far there has been little evidence of a link between living microbes and human health, highlighting specific gaps in the study and developing a plan to quantify the relationship between living microbial consumption and population health outcomes.
-
JEM: Researchers have found new particles in the blood of patients with sepsis
Time of Update: 2020-12-18
scientists are the first to find these particles, known as elongated neutral granulocyte-derived structures (ENDS), that break down immune cells and change shape as they pass through the body.
compared to healthy subjects, the researchers showed that ENDS detection rates were about 100 times higher in patients with sepsis.
-
Protein degradation agents become a big hit! AbbVie announced more than $1 billion in partnership, this time targeting cancer and immune diseases
Time of Update: 2020-12-16
On December 2nd AbbVie, the pharmaceutical giant, announced a global strategic partnership with Precision Medicines, a precision medicine company, to develop and commercialize innovative small molecule therapies that target hard-to-drug proteins.
-
GSK Bellevue mono-anti-new adaptive disorders were approved
Time of Update: 2020-12-16
On December 7, GlaxoSmithKline's mono-neo-adhesive disorder was approved by NMPA for use in patients 5 years of age and older who still have high disease activity (e.g., antids-DNA antibody-positive and low supplements, SELENA-SLEDAI score ≥8) on the basis of conventional treatment.
-
A sore throat nearly killed him! Expert: These kinds of sore throats, don't drag!
Time of Update: 2020-12-16
may cause sore throat, difficulty swallowing, neck lymphatic swelling, ear pain and other symptoms, accompanied by fever, poor breathing.
-
Br J Oral Maxillofac Surg: Tumor Necrotizer-α (TNF-α) inhibitors associated with jaw necrotasia and myelitis: a systematic review
Time of Update: 2020-12-16
all studies have a high risk of bias, limited data suggest that some patients may have ONJ/OM as a result of the treatment of TNF-α inhibitors.
-
Cell Death Differ: Pomone Primidone effectively inhibits RIPK1-driven cell death and inflammatory response
Time of Update: 2020-12-16
addition, in patients with COVID-19, it can improve or prevent multi-organ failure caused by cytokine release in the event of an excessive inflammatory response.
a comprehensive immunologic test of p-RIPK1 in respiratory endocyst cells in COVID-19 patients, the results provide a strong basis for evaluating the efficacy of the drug paracetones in over-inflammatory states.
-
Pain! Sore throat, sore neck, sore ears, headache... Hangzhou Dabo's disease, everyone can get!
Time of Update: 2020-12-16
" can no longer bear him to come to the hospital near home, the doctor considered may be pharyngitis, but laryngoscopy did not find abnormalities, taking into account the high C-reactive protein (inflammatory indicators), the disease was oral and intravenous anti-inflammatory treatment for several days, but Macdabo felt the situation did not ease, pain even sleep is affected.
-
Gastroenterology: Equsimod 2 mg or effective treatment for ulcerative colitis
Time of Update: 2020-12-16
, the results showed that in patients with moderate to severe active ulcerative colitis, 2 mg of equsimod improved clinical and endoscopic results.
-
BMJ: Active routine treatment of early rheumatoid arthritis and three different biological treatments
Time of Update: 2020-12-16
outcome was that the groups adjusted for the remission of clinical disease activity indicators at 24 weeks compared to conventional treatment (CDAI≤2.8).
the results highlighted the effectiveness and safety of active conventional therapy based on a combination of methotrexate and corticosteroids, but Abrasip's treatment was significantly better in early treatment of rheumatoid arthritis.
-
34-year-old Hangzhou woman has a parasite on her leg! It turned out she did it...
Time of Update: 2020-12-16
She said the wound, not long ago in Zhejiang University Medical College affiliated with the first hospital for day surgery left, doctors cut a lump from her left calf, pathological results show that there are many "parasites" hidden inside, which made her feel a cold sweat.
